RT Journal Article
SR Electronic
T1 Huntingtin Interacting Protein 1 (HIP1) autoantibodies as a novel potential surrogate marker for Rheumatoid Arthritis: Pilot Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.07.22279672
DO 10.1101/2022.09.07.22279672
A1 Surbhi,
A1 Goel, Ayushi
A1 Chaturvedi, Ved
A1 Verma, Sneha
A1 Rawat, Sonia
A1 Ganguly, Nirmal Kumar
A1 Mittal, Shivani Arora
YR 2023
UL http://medrxiv.org/content/early/2023/03/29/2022.09.07.22279672.abstract
AB Rheumatoid Arthritis (RA), an autoimmune disease, primarily affects synovial joints but has systemic manifestations upon progression. Considering limited specific diagnostic and prognostic biomarkers, identifying the disease early and monitoring its progression is important. Previous reports have shown that Huntingtin Interacting Protein 1 (HIP1) is over-expressed in rat synoviocytes, and its autoantibodies in sera of some cancers has diagnostic relevance. Here, we explored HIP1 and its autoantibody levels along with Th1/Th2/Th17 cytokines in sera of RA patients for their potential as surrogate markers. Relative level of autoantibodies to HIP1 was detected using an in-house developed ELISA. HIP1 expression was found comparable in RA patients and controls. HIP1 autoantibodies were found significantly raised in RA patients (p=0.002) and were higher in patients with active disease, thereby correlating with disease progression (p=0.042). Elevated Th1 and IL-6 cytokines (p=0.024) were found in a subset of patients with active disease, coinciding with their pro-inflammatory profile. This is the first report demonstrating a humoral immune response against HIP1 in RA patients, correlating with an active disease status. Further studies in a larger cohort are required to validate this as a surrogate marker.Key Points⍰ HIP1 autoantibodies are significantly increased in sera of RA patients.⍰ HIP1 autoantibodies correlate with active disease in RA patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Delhi Rheumatology Association & Sir Ganga Ram Hospital. We would also like to thank Council of Scientific and Industrial Research (CSIR) for providing Junior Research Fellowship to Ms Surbhi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Sir Ganga Ram Hospital (EC/07/19/1558)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors